CancerDrs

Lung Cancer clinical trials in Nevada

11 actively recruiting lung cancer trials at 8 sites across Nevada.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Nevada:
  • Carson Tahoe Regional Medical Center — Carson City, Nevada
  • Cancer and Blood Specialists-Henderson — Henderson, Nevada
  • Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
  • Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
  • Las Vegas Cancer Center-Henderson — Henderson, Nevada
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Nevada:
  • Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Nevada:
  • Renown Regional Medical Center — Reno, Nevada
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Nevada:
  • Renown Medical Group - Oncology/Hematology /ID# 247942 — Reno, Nevada
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Nevada:
  • OptumCare Cancer Care at Charleston — Las Vegas, Nevada
  • OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada
View on ClinicalTrials.gov →
Recruiting Academic/Other

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is …

Sponsor: University of Rochester
NCT ID: NCT06073431
Sites in Nevada:
  • Carson Tahoe Regional Medical Center — Carson City, Nevada
  • Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
  • OptumCare Cancer Care at Seven Hills — Henderson, Nevada
  • Comprehensive Cancer Centers of Nevada-Southeast Henderson — Henderson, Nevada
  • Urology Specialists of Nevada - Green Valley — Henderson, Nevada
View on ClinicalTrials.gov →
Recruiting Industry

GEMINI-NSCLC: NSCLC Biomarker Study

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and di…

Sponsor: Tempus AI
NCT ID: NCT05236114
Sites in Nevada:
  • OptumCare Cancer Care — Las Vegas, Nevada
  • Hope Cancer Care of Nevada — Las Vegas, Nevada
  • Cancer Care Specialists Reno — Reno, Nevada
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Statewide Optimization of Lung Cancer Screening Utilizing the QUILS™ System in Nevada and Mississippi: State-Based Initiative Component

This clinical trial studies whether a Quality Implementation of Lung Cancer Screening (QUILS™) System state-based initiative (SBI) intervention works to improve the statewide capacity for implementing and sustaining lung cancer screening i…

Sponsor: Timothy Mullett
NCT ID: NCT07682597
Sites in Nevada:
  • Mt. Grant General Hospital — Hawthorne, Nevada
  • Desert View Hospital — Pahrump, Nevada
  • Renown Regional Medical Center — Reno, Nevada
  • Sierra Medical Center — Reno, Nevada
  • Sunrise Health — Winchester, Nevada
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19